Price controls and a greater role for the US FDA may foreshadow difficult times for the biotech industry in the coming year
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal
Australia and New Zealand Health Policy Open Access 01 June 2007
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
https://doi.org/10.1038/News@Nature(06Nov2006)News
https://doi.org/10.1038/News@Nature(13Nov2006)News
Web links
The Biotechnology Industry Organization
Rights and permissions
About this article
Cite this article
Vastag, B. The policy outlook from the Hill. Nat Biotechnol 25, 13–16 (2007). https://doi.org/10.1038/nbt0107-13
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0107-13
This article is cited by
-
Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal
Australia and New Zealand Health Policy (2007)
